title: Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
abstract: BACKGROUND
  Potent inhibition of the platelet glycoprotein IIb/IIIa receptor has improved the acute outcome of patients presenting with acute coronary syndromes (ACS). For patients with ACS undergoing percutaneous balloon angioplasty without coronary stenting in the era of platelet glycoprotein IIb/IIIa blockade, the long-term prognosis is less clear.
  
  
  OBJECTIVE
  To examine the six-month outcome of patients who received eptifibatide within a randomized clinical trial and subsequently underwent balloon angioplasty.
  
  
  METHODS
  Patients included in this substudy were enrolled in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, a randomized study evaluating the efficacy of eptifibatide in reducing the incidence of death or nonfatal myocardial infarction (MI) in non-ST segment elevation ACS. During the index hospitalization, 1151 (12.2%) of the PURSUIT patients underwent percutaneous balloon angioplasty without coronary stenting.
  
  
  RESULTS
  Eptifibatide was associated with a significant reduction in the adjudicated composite end point of death or MI at six months after randomization in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) (P=0.037). A trend toward a beneficial effect was evident before the procedure (4.7% versus 6.9%; P=0.13) and at 30 days (12.1% versus 15.3%; P=0.12). The incidence of repeat revascularization was relatively low for patients undergoing PTCA, with no difference observed between the eptifibatide and placebo groups (16.3% versus 14.8%; P=0.51).
  
  
  CONCLUSIONS
  Eptifibatide was associated with a sustained beneficial effect to six months in patients with ACS undergoing PTCA. It reduced the incidence of preprocedural MI. The rate of repeat revascularization at six months was low and was not significantly altered by eptifibatide.
authors.affiliation: University of Ottawa Heart Institute, Ottawa, Ontario. mlabinaz@ottawaheart.ca
authors.forename: Marino
authors.initials: M
authors.lastname: Labinaz
authors.forename: Padma
authors.initials: P
authors.lastname: Kaul
authors.forename: Robert A
authors.initials: RA
authors.lastname: Harrington
authors.forename: Wei-Ching
authors.initials: WC
authors.lastname: Chang
authors.forename: Neal S
authors.initials: NS
authors.lastname: Kleiman
authors.forename: Maarten L
authors.initials: ML
authors.lastname: Simoons
authors.forename: Eric
authors.initials: E
authors.lastname: Boersma
authors.forename: K Martijn
authors.initials: KM
authors.lastname: Akkerhuis
authors.forename: Robert M
authors.initials: RM
authors.lastname: Califf
authors.forename: Paul W
authors.initials: PW
authors.lastname: Armstrong
mesh_terms: D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary / Q000379:methods* / Q000706:statistics & numerical data; D017023:Coronary Angiography; D003327:Coronary Disease / Q000453:epidemiology / Q000628:therapy*; D004311:Double-Blind Method; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D019233:Retreatment / Q000706:statistics & numerical data; D012307:Risk Factors; D016019:Survival Analysis; D013577:Syndrome; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide